2-(3-[4-[2-(二乙基氨基)乙氧基]-3,5-二碘苯甲酰基]-1-苯并呋喃-2-基)乙酸 (2S)-丁-2-基酯 | 335148-45-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(3-[4-[2-(二乙基氨基)乙氧基]-3,5-二碘苯甲酰基]-1-苯并呋喃-2-基)乙酸 (2S)-丁-2-基酯
• 中文别名: 2-(3-[4-[2-(二乙基氨基)乙氧基]-3,5-二碘苯甲酰基]-1-苯并呋喃-2-基)乙酸(2S)-丁-2-基酯
• 英文名称: Budiodarone
• 英文别名: (S)-sec-butyl 2-(3-(4-(2-(diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl)acetate；ATI-2042；[(2S)-butan-2-yl] 2-[3-[4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl]-1-benzofuran-2-yl]acetate
• CAS: 335148-45-3
• 化学式: C₂₇H₃₁I₂NO₅
• 分子量: 703.356
• InChiKey: ZXOSVKYCXLTVGS-KRWDZBQOSA-N

物化性质

• 沸点：
  672.2±55.0 °C(Predicted)
• 密度：
  1.580±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  35
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  69
• 氢给体数：
  0
• 氢受体数：
  6

制备方法与用途

Budiodarone（ATI-2042）是Amiodarone（HY-14187）的类似物，其半衰期为7小时。它能抑制钠、钾和钙离子通道，并作为一种抗心律失常剂用于房颤的研究。

反应信息

• 作为反应物：
  描述：

  2-(3-[4-[2-(二乙基氨基)乙氧基]-3,5-二碘苯甲酰基]-1-苯并呋喃-2-基)乙酸 (2S)-丁-2-基酯 、 L-酒石酸 以 水 、 异丙醇 为溶剂， 生成 budiodarone tartrate
  参考文献：
  名称：

  WO2007/11835

  摘要：

  公开号：
• 作为产物：
  描述：

  [3-(4-hydroxy-3,5-diiodo-benzoyl)-benzofuran-2-yl]-acetic acid (S)-sec-butyl ester 、 2-二乙氨基氯乙烷盐酸盐 在 potassium hydrogencarbonate 作用下， 以 水 、 甲苯 为溶剂， 生成 2-(3-[4-[2-(二乙基氨基)乙氧基]-3,5-二碘苯甲酰基]-1-苯并呋喃-2-基)乙酸 (2S)-丁-2-基酯
  参考文献：
  名称：

  WO2007/11835

  摘要：

  公开号：

文献信息

• Antiarrhythmic Precursor Compounds, Methods Of Synthesis And Methods Of Use
  申请人：Druzgala Pascal

  公开号：US20070060640A1

  公开（公告）日：2007-03-15

  The invention comprises compounds of Formula 1: wherein, R 1 is independently H or halogen; R 2 is, for example, H or —R 10 —NR 11 R 12 , and wherein R 10 is C 1 -C 6 alkyl, and R 11 and R 12 are independently H, C 1 -C 4 alkyl, and hydrates, solvates, salts and tautomers thereof. The invention further comprises methods for making the compounds of the invention and methods for making compounds useful in the treatment or prevention of cardiac arrhythmia from the compounds of the invention.

  本发明涉及一种公式1的化合物：其中，R1独立地为H或卤素；R2例如为H或-R10-NR11R12，其中R10为C1-C6烷基，R11和R12独立地为H、C1-C4烷基，以及其水合物、溶剂化合物、盐和互变异构体。本发明还涉及制备本发明化合物的方法以及用于制备治疗或预防心律失常的化合物的方法，这些化合物来自本发明化合物。
• BUDIODARONE FORMULATIONS
  申请人：Armetheon, Inc.

  公开号：US20140309296A1

  公开（公告）日：2014-10-16

  The present invention relates to budiodarone formulations which comprise a solution comprising benzyl alcohol and budiodarone, wherein the budiodarone has an aqueous solubility of about 200 mg/ml to about 1250 mg/ml when contacted with an aqueous solution. The budiodarone formulations can be highly concentrated and stored with stability, yet the formulations are also dilutable and can be delivered to a subject with ease and immediacy.

  本发明涉及包含苯甲醇和布地奥酮的溶液的布地奥酮制剂，其中当与水溶液接触时，布地奥酮的水溶性约为每毫升200毫克至1250毫克。布地奥酮制剂可以高度浓缩并具有稳定性，但制剂也可以稀释并且可以轻松快速地输送给受试者。
• Antiarrhythmic precursor compounds, methods of synthesis and methods of use
  申请人：Aryx Therapeutics, Inc.

  公开号：EP2145881A1

  公开（公告）日：2010-01-20

  The invention comprises compounds of Formula 1: wherein, R1 is independently H or halogen; R2 is, for example, H or --R10-NR11R12, and wherein R10 is C1-C6 alkyl, and R11 and R12 are independently H, C1-C4 alkyl, and hydrates, solvates, salts and tautomers thereof. The invention further comprises methods for making the compounds of the invention and methods for making compounds useful in the treatment or prevention of cardiac arrhythmia from the compounds of the invention.

  本发明包括式 1 的化合物： 其中，R1独立地为H或卤素；R2例如为H或--R10-NR11R12，其中R10为C1-C6烷基，R11和R12独立地为H、C1-C4烷基，及其水合物、溶液、盐和同系物。本发明进一步包括制造本发明化合物的方法和用本发明化合物制造用于治疗或预防心律失常的化合物的方法。
• Novel Compounds For Treatment of Cardiac Arrhythmia and Methods of Use
  申请人：Druzgala Pascal

  公开号：US20080114059A1

  公开（公告）日：2008-05-15

  The subject invention provides novel compounds for treatment of cardiac arrhythmia and methods of use.
• METHODS FOR STROKE REDUCTION IN ATRIAL FIBRILLATION PATIENTS
  申请人：Milner Peter G.

  公开号：US20110136779A1

  公开（公告）日：2011-06-09

  The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering a multiple ion channel blocker anti-arrhythmic to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of multiple ion channel blocker and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of the multiple ion channel blocker may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling. In some methods of the invention, budiodarone is administered 400 mg BID or more preferably 600 mg BID.